realization, many students no longer want to work in the biomedical centers. Worried about the socioeconomic crisis in the country, the Cuban Communist Party in coordination with the government in 1998 initiated a political crusade against scientists occupying prominent positions who defended ideas that diverged from the hard line dictated by the Party. The result was the firing or demotion of many senior scientists (myself included) and the imposition of political, rather than scientific, issues in the scientific centers. As a direct result of these policies, many scientists have been forced to abandon the centers or to leave Cuba and continue their careers in exile. The response of Cuban officials has been to reinforce political constraints further in the centers, engendering a reiterative degeneration that is mirrored by deteriorating public health services and educational standards14. The government and the internal media attempt to give a more positive view of the situation15, but with little success. No one complains publicly or to outsiders about these problems because there is no freedom to criticize any aspect of Cuba's social, economic, and political establishments. The situation persists, restricting the potential of our youth and all but extinguishing the once-bright hope of real scientific development in our country.
SQ solves Status quo solves – US biotech industry thriving now Paragon 12 - Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. (Paragon Report, “Biotech Industry Thriving in 2012 -- Number of FDA Approvals Growing”, 6/14/12, - nasdaq-isis-1669377.htm, HW) The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up over 22 percent year-to-date. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. A flurry of mergers & acquisitions activity and a growing number of FDA approvals have been contributing factors to the industry's recent boom. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Apricus Biosciences Inc. (NASDAQ: APRI) ¶ "In 2011, the U.S. FDA approved 30 new drugs, compared to 21 in 2010. We see an improving trend for FDA first cycle approvals and a rise in the rate of new drug approvals for rare diseases. We think these trends are helping to boost investor sentiment toward the agency, after years of criticism stemming from its inconsistency in making and communicating its decisions ," Steven Silver, S&P Capital IQ Analyst, said in a recent note.
You've reached the end of your free preview.
Want to read all 162 pages?
- Fall '16
- jane smith
- International Relations, Raúl Castro